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Abstract  
BACKGROUND: The pandemic of obesity is striking heavily worldwide and particularly among the affluent Gulf 
States where it is expected to continue to rise along with its complications. 
AIM: To examine the link between liver fat infiltration and abdominal fat amount using plain computer-assisted 
tomography (CT). 
METHODS: Fifty patients visiting the obesity clinic of “King Fahd Specialist Hospital” or Dr Suliman Alhabeeb 
Hospital between January 2015 and April 2016 were included. Liver and splenic attenuation dimensions were 
undertaken with three hepatic regions of interests (ROIs) and two ROIs from the spleen. The liver attenuation 
indices (LAIs) that were measured liver parenchymal attenuation (CTLP), liver/splenic attenuation ratio (LS 
ratio)and the (3) difference between liver and splenic attenuation (LS dif) and based on this LS dif The patients 
were grouped as LS dif greater or less than 5. Abdominal fat was evaluated utilising a 3 mm chop CT scan 
starting from the umbilicus; then computed by a workstation. The abdominal fat was classified as total fat (TF) and 
the sub-compartments of visceral adipose (fat) (VF), and subcutaneous fat (SF). 
RESULTS: Twenty-six of the participants were males. The mean (SD) of the age and BMI was 48 (14.9) years 
and 32.05 (8.3) kg/m
2
 respectively.The BMI and body Wt had a moderate negative correlation with the liver 
attenuation indices CTLP, LS ratio, LS diff (r = -0.417, -0.277, -0.312 and 0.435, -0.297, -0.0297), respectively. A 
very strong negative correlation between fatty liver, LS ratio and CTLP was found (-0.709, -0.575) respectively. 
CONCLUSION: Plain computed tomography can reliably be used as a survey device for fatty liver disease. 
 
 
 
 
Introduction 
 
The pandemic of obesity is striking heavily 
worldwide and particularly among the affluent 
countries like the Gulf States where it is expected to 
continue to rise as projected by the previous reaserch 
[1, 2]. Consequently, its complications are expected to 
follow a similar trend one of which is the fatty liver 
disease. Fatty liver is a disease where surplus 
adipose, mainly triglycerides, compiles to make more 
than 5% of the hepatic weight [3]. For patients with no 
history of indulgent alcohol drinking, this condition is 
recognised as the non-alcoholic fatty liver disease 
(NAFLD) and it commonly presents in the context of 
metabolic syndrome [4]. NAFLD is eminently 
ubiquitous worldwide and its clinicopathologic 
spectrum encompasses the grades from 
uncomplicated fatty change to nonalcoholic 
steatohepatitis (NASH), which can evolve to cirrhosis 
[5, 6]. NAFLD is common in the obese and is 
connected with the metabolic syndrome. Such 
abnormalities are associated with heightened risk of 
cardiovascular incidents [6].  
Among similar disease entities, central 
obesity is closely linked to high metabolic risk, 
independent of whole-body obesity. Early detection of 
NASH (the most advanced stage of NAFLD that can 
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progress to cirrhosis) using non-invasive tools helps in 
identifying those in jeopardy of developing 
hepatocellular carcinoma. Visceral adiposity (VF) is 
more strongly connected with increased metabolic risk 
among the category of central obesity, than 
subcutaneous fat (SF) [7]. In routine imaging 
modalities ultrasound scan (US), computer assisted 
tomography (CT), and magnetic resonance (MR) 
NAFLD is often detected in patients with normal body 
mass indices (BMIs). In contrast, it is also often that 
normal liver parenchyma is found in obese patients. 
Therefore, it is likely that NAFLD might have a tighter 
connection with abdominal VF compared to the total 
fat (TF). Liver biopsy is the best available test to 
diagnose fatty liver [8]. However, they are invasive, 
painful and require bed rest for six hours or more; 
furthermore, they modestly increase the mortality 
hazard [9]. Given the potential hazards, biopsies are 
not regularly undertaken in all patients. Imaging 
techniques have surfaced as a substitute for biopsy, 
where they include US, CT, and MR, and are now 
widely used. Of these, we have selected CT as the 
method for this study [9]. CT attenuation 
measurements of the liver were tightly linked with 
histologically proven hepatic steatosis [10]. Finding 
liver attenuation to be considerably lower than splenic 
attenuation is a dependable gauge of fatty liver [11]. 
Therefore, CT scan can be utilised as a non-invasive 
test to prove the presence of hepatic steatosis. There 
are few prior studies that investigated the relationship 
between fatty liver and abdominal adiposity using CT 
[12]. Therefore the current study was conducted to 
investigate the possible correlations between hepatic 
fat infiltrations expressed as CT liver enfeeblement 
readings (in Hounsfield units (HU) and abdominal 
adiposity amount, which was quantitated directly from 
CT.  
 
 
Material and Methods 
 
Patient selection 
A cross-sectional study was conducted at the 
outpatient clinic of King Fahd Specialist Hospital and 
Dr Suliman Alhabeeb Hospital, Qassim, Kingdom 
Saudi Arabia for self-perception during the period of 
January 2015 through April 2016. The sample size 
was calculated as per the following equation 
Total sample size = N = [(Zα+Zβ)/C]
2
 + 3 = 47 
The standard normal deviate for α = Zα = 
1.960, the standard normal deviate for β = Zβ = 0.842, 
type 1 error was regarded as 0.05, type 2 error was 
regarded as 0.2, the expected r was regarded as 0.4  
After signing an informed consent, the 
following information was collected for each patient on 
a well-structured questionnaire including sex, age, 
height; body weight (WT), BMI, history of alcohol 
consumption, the blood pressure was measured. 
Fasting serum cholesterol, Triglyceride level (TG), and 
low-density lipoprotein (LDL) were measured. Those 
who had a history of alcohol consumption, bile duct 
dilatation, hepatic mass, viral hepatitis, liver cirrhosis, 
and hepatic surgery were excluded. 
A fat protocol CT was conducted on each 
patient. According to World Health Organization, a 
BMI over 25 kg/m
2
 is labelled as overweight and a 
BMI of over 30 kg /m2 as obese [13]. This study was 
approved by the Qassim University Review Board on 
bases complying with the principles of the Declaration 
of Helsinki.  
 
CT liver enfeeblement quantitation  
The liver and the splenic attenuation were 
assessed using plain CT scans. The evaluation was 
carried with the voltage of the tube being 120 kVp, a 
tube current of 50 mAs, and a tube circumrotation 
time of 750 ms. with the patient in the supine position, 
five consequent axial slices 3 mm in density were 
captured at approximately the mid-part of the liver 
shadow on tomogram. Among the five consecutive 
chops, we randomly selected one image for 
quantitation of the hepatic and splenic enfeeblement 
for each patient. Five regions of interests (ROIs) were 
determined in the liver, escaping vessels, bile ducts, 
calcifications, and artefacts; similarly, four ROIs were 
determined in the spleen. The higher most and 
lowermost measurements were excluded on gauging 
the mean enfeeblement of the hepatic and splenic 
dimensions. As such, three liver measurements and 
two splenic dimensions were utilised to gauge the 
mean dimensions. We extracted the liver attenuation 
indices (LAIs) from the calculated mean enfeeblement 
measurements of the liver and spleen. The LAIs 
included: (1) liver parenchymal attenuation (CTLP; 
mean liver attenuation); (2) liver / spleen attenuation 
ratio (LS ratio; mean liver attenuation /mean splenic 
attenuation); and (3) difference between liver and 
spleen attenuations (LS dif; mean hepatic attenuation 
- mean splenic attenuation) 5. The patients were 
grouped into two groups based their LS dif. LS dif is 
one of the popular reference measurements for 
grading fatty liver with CT [11]. Subjects with an LS dif 
greater than 5 were labelled as normal. Patients with 
an LS dif less than 5 were labelled as having fatty 
liver. 
 
Analysis of the abdominal adipose 
dispersal  
All the patients were subjected to abdominal 
adipose dispersal analysis. With the iliac crest as the 
starting point, 5 slices 3 mm in density were scanned 
in a superior direction to measure the VF and TF 
regions. The iliac crest coincides with the L4/5 level as 
well the umbilical level. The cross-sectional surface 
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regions (cm
2
) of variant abdominal fat regions were 
automatically analyzed in three dimensions using 
commercially accessible CT software (Philips EBW2 
version 3.0). The fat tissue width was driven 
electronically by setting the attenuation 
measurements for an area of interest within a range of 
-175 to -25 HU. The center of the aperture was 
adjusted at 100 and the girth was set at 150. The VF 
area was estimated by determination of the intra-
abdominal cavity size at the internal facet of the 
abdominal wall encompassing the cavity. Gaseous 
and other intestinal contents were excluded. 
Abdominal adiposity consists of TF, VF, and SF. The 
SF width was calculated by subtracting the VF width 
from the TF width. The ratio of VF to SF (VS ratio) 
was also calculated. 
 
Statistical analysis 
SPSS statistical software (version 20.0 for 
Windows; SPSS Inc., Chicago, IL, USA) was utilised 
for statistical evaluation. The significance value (ᾳ) 
level was set at a P-value of 0.05 for all tests. We 
used the bivariate spearman correlation analysis to 
assess the correlation between LAIs and TF, VF, and 
SF after checking for the normality of the data 
distribution using Shapiro-Wilk normality test. 
Kendall’s tau-b correlation was used to assess the 
relationships between the LAIs and BMI, WT, TG, and 
LDL and between BMI and TF, VF, and SF as well as 
the TF, VF, SF, CTLP, LSRatio and Fatty liver (See 
Table 3).  
 
 
Results 
 
A total number of 50 patients participated in 
the study, 26 of them were males, with a mean age of 
48 ± 14.9 years, while the mean BMI was 32.05 ± 8.3 
kg/m
2
, see Table 1.  
Table 1: Means liver attenuation indices, splenic attenuation, 
BMI, lipids, and weight 
Mean(SD) of  
LDL mmol/L 2.88 (0.84) 
Cholesterol mmol/L 4.56 (0.94) 
LSratio (HFU) 1.10 (0.21) 
LSdiff (HFU) 4.70 (9.86) 
Median (interquartile) of  
BMI (Kg/m
2
) 30.4 (26.5-36.7) 
Wt (Kg) 80 (70.9−93.6) 
Triglycerides mmol/L 1.2 (0.9-1.7) 
CTLP (HFU) 56 (44-60) 
VF (cm) 102.5 (98.8-106.5) 
TF (cm) 111.8 (108.4-116.3) 
SF (cm) 8.5 (3.2-14.8) 
 
Of the participating subjects 6/50 (12%), 
18/50 (36%) and 26/50 (52%) were normal weight, 
overweight and obese respectively. The prevalence of 
subjects suffering hepatic steatosis followed an 
increasing trend among the above BMI groups where 
it increased from 10% among normal subjects to 30% 
among the overweight group to reach its peak of 60% 
among the obese patients. While BMI and body 
weight showed a moderate negative correlation with 
the liver attenuation indices CTLP, LSratio, LSdiff (r = 
-0.417, -0.277, -0.312 and 0.435, -0.297, -0.0297) 
respectively. There was a positive correlation between 
weight and CTLP (r = 0.435), There was no 
correlation between lipids and LAIs see Table 2.  
Table 2: Correlation between the liver attenuation indices, BMI, 
weight and lipids 
Variables  TF SF LS 
ratio 
LS diff CTLP Chol LDL TG BMI Wt 
VF 0.163 -0.553 -0.015 -0.034 -0.234 0.158 0.185 -0.155 0.219 0.344 
TF  0.624 0.175 0.150 0.120 0.274 0.200 0.89 -0.184 -0.133 
SF   0.081 0.074 0.252 -0.043 -0.110 0.142 -0.177 -0.244 
LS ratio    0.995 0.791 0.101 0.118 0.140 -0.277 -0.271 
LS diff     0.829 0.093 0.117 0.066 -0.312 -0.297 
CTLP      0.084 0.142 0.116 -0.417 0.435 
Chol       0.852 0.068 -0.172 0.007 
LDL        0.259 -0.322 -0.146 
TG         0.130 0.130 
BMI          0.824 
 
On the contrary, LAIs and BMI have no 
correlation with the abdominal fat volume. A very 
strong negative correlation was found between fatty 
liver, LS ratio and CTLP (-0.709, -0.575) respectively 
see Table 3. 
Table 3: Correlation between hepatic attenuation indices and 
total fat, visceral fat, and subcutaneous fats 
variables TF SF Fatty liver CTLP LS ratio 
VF 0.117 -0.421 -0.018 -0.150 -0.021 
TF  0.474 -0.061 0.072 0.124 
SF   0.036 0.170 0.063 
Fatty liver    -0.575 -0.709 
CTLP     0.637 
 
 
 
Discussion 
 
The main finding of the current study is 
negative correlation between BMI, weight and the liver 
attenuation indices. Saran et al described similar 
findings in their study among an Indian population 
[11]. Moreover, the current study showed that CTLP 
and LS ratio both show very strong negative 
correlations with hepato-steatosis, such a correlation 
has been described by Rockall et al. [14]. Park et al 
stated that an LS ratio 0.8, an LSdif of -9, and a CTLP 
42 granted the highest cut-off values with a yield of 
100% specificity for the detection of macrovesicular 
steatosis of 30% or more (the limit of acceptability for 
donation) [15]. Another important finding of our study 
is the increasing prevalence trend of hepatic steatosis 
among the different BMI groups peaking up to 60% of 
obese patients. Such a trend has been described by a 
group of researchers among an American population 
where the prevalence peaked from 28% among 
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normal weight subjects to 67% among obese subjects 
[16]. NAFLD is strictly connected with characteristics 
of the metabolic syndrome [17]. The amount of 
intrahepatic fat is closely correlated to the features of 
the metabolic syndrome [18]. The current study has 
added to the evidence of the utility of plain computed 
tomography in the diagnosis of non-alcoholic 
steatohepatitis where one of its main findings is the 
moderate negative correlation between the liver 
attenuation indices and the body mass index. Similar 
relations has been pointed to by different researchers 
not only this but further, it has been described that a 
hepatic attenuation value (CTLP) that is significantly 
less than the splenic attenuation value is a reliable 
pointer to the presence of fatty liver [19, 20].  
Furthermore, the use of CT in the diagnosis of 
mild hepato-steatosis is unreliable; such a remark is 
likely to be observed in the study as an appreciable 
number of the subjects involved in our study are likely 
to have mild hepatic steatosis as seen from their BMI.  
 In conclusion, plain computed tomography 
can reliably be used as a survey device for fatty liver 
disease. 
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